⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231035 | 0.93 | — | — | |
| SCHEMBL165344 | 0.93 | — | — | |
| SCHEMBL1397090 | 0.90 | — | — | |
| SCHEMBL11773212 | 0.90 | — | — | |
| SCHEMBL19297 | 0.90 | — | — | |
| SCHEMBL25238188 | 0.90 | — | — | |
| SCHEMBL11777486 | 0.90 | — | — | |
| SCHEMBL7393104 | 0.90 | — | — | |
| SCHEMBL168533 | 0.86 | — | — | |
| SCHEMBL28939344 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023247595-A1 | PYRAZOLOPYRAZINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | claimed |
| EP-0421752-A2 | Substituted acrylamido-penicillanic acid derivatives | Beecham Group p.l.c. (GB) | 1991-04-10 | — | — | EP | claimed |
| EP-4397309-A2 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024129963-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240182494-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240158381-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240132521-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024059563-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024044570-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-1313710-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Pfizer Products Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1305295-A1 | IMIDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030083352-A1 | Synthesis of imidazole intermediates | PFIZER INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030078252-A1 | Thiazole derivatives | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1256578-A1 | Thiazole derivatives and their use as cdk inhibitors | Pfizer Products Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020119963-A1 | Imidazole derivatives | PFIZER PRODUCTS INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020103185-A1 | Pyrazole derivatives | PFIZER PRODUCTS INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002018346-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002010141-A1 | IMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-02-07 | — | — | WO | disclosed |